Evidence map›Paper›PMID 24793443›Full record

GuidelineJournal of clinical lipidology

An assessment by the Statin Muscle Safety Task Force: 2014 update.

Robert S Rosenson, Steven K Baker, Terry A Jacobson, Stephen L Kopecky, Beth A Parker, The National Lipid Association's Muscle Safety Expert Panel

Registry-linked trialAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Journal of clinical lipidology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03696940. Cited by 153 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
153citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03696940 phase3unknown status

Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina

Ran2018Enrolled120Registered outcomes6Posted comparisons0ConditionsCardiovascular Risk Factor, DyslipidemiasArmsAtorvastatin 10mg, L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
PMID 27046161PMID 25537708PMID 24793440PMID 24793441PMID 16034009PMID 26939026PMID 17039901PMID 23190071PMID 19604523PMID 25915661PMID 19618992PMID 16384561other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

153 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy.European journal of clinical pharmacology · 2018 · on this map
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

93 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Robert S RosensonMount Sinai Heart, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA. Electronic address: robert.rosenson@mssm.edu.
Steven K BakerMcMaster University, Hamilton, ON, Canada.
Terry A JacobsonEmory University, Atlanta, GA, USA.
Stephen L KopeckyMayo Clinic, Rochester, MN, USA.
Beth A ParkerDepartment of Cardiology, Henry Low Heart Center, Hartford Hospital, Hartford, CT, USA.
The National Lipid Association's Muscle Safety Expert Panel

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The National Lipid Association's Muscle Safety Expert Panel was charged with the duty of examining the definitions for statin-associated muscle adverse events, development of a clinical index to assess myalgia, and the use of diagnostic neuromuscular studies to investigate muscle adverse events. We provide guidance as to when a patient should be considered for referral to neuromuscular specialists and indications for the performance of a skeletal muscle biopsy. Based on this review of evidence, we developed an algorithm for the evaluation and treatment of patients who may be intolerant to statins as the result of adverse muscle events. The panel was composed of clinical cardiologists, clinical lipidologists, an exercise physiologist, and a neuromuscular specialist.

Indexed as

Cardiovascular DiseasesCreatine KinaseEvidence-Based MedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipoproteinemia Type IIMuscle, SkeletalMuscular DiseasesMyalgiaVitamin DCreatine KinaseHydroxymethylglutaryl-CoA Reductase InhibitorsVitamin DMuscle adverse eventsMyalgiaMyopathyNeuromuscular testingRhabdomyolysisStatin intoleranceStatins

Identifiers

PMID24793443

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.